Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
The data are positive, but might not do much for the company’s sales.
Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…